Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics Equivalence of Antareit vs Riopan in Healthy Volunteers
NCT06552624Completed
- Sponsor
- Valenta Pharm
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of magaldrate in gastroesophageal reflux disease (GERD), gastric ulcer, duodenal ulcer and 1 more (2 arms), sponsored by Valenta Pharm. Primary endpoint: Area under the curve potential of hydrogen above the baseline. Started Jul 2021; status: completed.
02
Drugs
magaldrate
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcerduodenal ulcerGastrointestinal diseases
Beyond the preview
Go deeper on NCT06552624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552624.